A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 08 May 2019
Price : $35 *
At a glance
- Drugs Efinopegdutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Research & Development
- 03 May 2019 Status changed from active, no longer recruiting to completed.
- 08 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2018 Planned End Date changed from 13 Mar 2019 to 4 Apr 2019.